Maintenance therapy with pemetrexed and erlotinib resulted in improved progression-free survival compared with second-line therapy at disease progression. In the second-line setting, pemetrexed ...
Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback